|
Office of Biotechnology Activities
|
National Institutes of Health - Office of Science Policy
|
| |
| RAC September 21, 2005 - Presentation Materials |
|
| 101st Meeting |
| Bethesda, Maryland |
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Call to Order and Opening Remarks |
|
|
| |
Diane Wara, M.D., Chair, NIH RAC |
|
|
| |
Webcast
|
|
| |
|
|
|
Gene Transfer Safety Assessment Board Report |
|
|
| |
RAC Reviewers: Steven Albelda, M.D., Helen Heslop, M.D., and Diane Wara, M.D. |
|
|
| |
Webcast
|
|
| |
|
|
|
RNAi and Its Potential Application as a Therapeutic Strategy |
|
|
| |
Natasha Caplen, Ph.D., National Cancer Institute,
National Institutes of Health |
|
|
| |
Slides
Webcast
|
|
| |
|
|
|
|
Discussion of Human Gene Transfer Protocol #0508-725 |
|
|
| |
A Phase I Pilot Study of Safety and Feasibility of Stem Cell Therapy for AIDS Lymphoma Using Stem Cells Treated with a Lentivirus Vector Encoding Multiple Anti-HIV RNAs |
|
|
| |
Amrita Krishnan, M.D., City of Hope National Medical Center,
Duarte, CA |
|
|
| |
Slides
Webcast
|
|
| |
|
|
|
A User�s Guide to FDA�s Draft Guidance: Gene Therapy Clinical Trials Observing Participants for Delayed Adverse Events |
|
|
| |
Carolyn A. Wilson, Ph.D., U.S. Food and Drug Administration |
|
|
| |
Slides
Webcast
|
|
| |
|
|
|
ADJOURN |
|
| |
|
Top of Page |
|
|
|
|
|